Have a personal or library account? Click to login
Telomere length and TERT polymorphisms as biomarkers in asbestos-related diseases Cover

Telomere length and TERT polymorphisms as biomarkers in asbestos-related diseases

Open Access
|Feb 2024

References

  1. Toyokuni S. Commentary on “mechanisms of asbestos-induced carcinogenesis” published in 2009. Nagoya J Med Sci 2023; 85: 13–5. doi: 10.18999/nagjms.85.1.13
  2. Hajj GNM, Cavarson CH, Pinto CAL, Venturi G, Navarro JR, de Lima VCC.. Malignant pleural mesothelioma: an update. J Bras Pneumol 2021; 47: e20210129. doi: 10.36416/1806-3756/e20210129
  3. Brims F. Epidemiology and clinical aspects of malignant pleural mesothelioma. Cancers 2021; 13: 4194. doi: 10.3390/cancers13164194.
  4. Gaudino G, Xue J, Yang H. How asbestos and other fibers cause mesothelioma. Transl Lung Cancer Res 2020; 9(Suppl 1): S39–46. doi: 10.21037/tlcr.2020.02.01
  5. Tallet A, Nault JC, Renier A Hysi I, Galateau-Sallé F, A Cazes A, et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene 2014; 33: 3748–52. doi: 10.1038/onc.2013.351
  6. Rossiello F, Jurk D, Passos JF, di Fagagna FA. Telomere dysfunction in ageing and age-related diseases. Nat Cell Biol 2022; 24: 135–47. doi: 10.1038/s41556-022-00842-x
  7. Lin J, Epel E. Stress and telomere shortening: insights from cellular mechanisms. Ageing Res Rev 2022; 73: 101507. doi: 10.1016/j.arr.2021.101507
  8. Wadowski B, De Rienzo A, Bueno R. The molecular basis of malignant pleural mesothelioma. Thorac Surg Clin 2020; 30: 383–93. doi: 10.1016/j.thorsurg.2020.08.005
  9. Berry TA, Belluso E, Vigliaturo R, Gieré R, Emmett EA, Testa JR, et al. Asbestos and other hazardous fibrous minerals: potential exposure pathways and associated health risks. Int J Environ Res Public Health 2022; 19: 4031. doi: 10.3390/ijerph19074031
  10. Pouliquen DL, Kopecka J. Malignant mesothelioma. Cancers 2021; 13: 3447. doi: 10.3390/cancers13143447
  11. Zhu W, Liu J, Li Y, Shi Z, Wei S. Global, regional, and national trends in mesothelioma burden from 1990 to 2019 and the predictions for the next two decades. SSM Popul Health 2023; 23: 101441. doi: 10.1016/j.ssmph.2023.101441
  12. Cancer in Slovenia 2018. Annual report. Zadnik V, Gašljević G, Hočevar M, Jarm K, Pompe-Kirn V, Strojan P, et al, editors. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Slovenian Cancer Registry; 2020.
  13. Štrbac, D, Dolžan V. Novel and future treatment options in mesothelioma: a systematic review. Int J Mo Sci 2022; 23: 1975. doi: 10.3390/ijms23041975
  14. Guo X, Lin L, Zhu J. Immunotherapy vs. chemotherapy in subsequent treatment of malignant pleural mesothelioma: which is better? J Clin Med 2023; 12: 2531. doi:10.3390/jcm12072531
  15. Okamoto K, Seimiya H. Revisiting telomere shortening in cancer. Cells 2019; 8: 107. doi: 10.3390/cells8020107
  16. Razgonova MP, Zakharenko AM, Golokhvast KS, Thanasoula M, Sarandi E, Nikolouzakis K, et al. Telomerase and telomeres in aging theory and chronographic aging theory (review). Mol Med Rep 2020; 22: 1679–94. doi: 10.3892/mmr.2020.11274
  17. Rampazzo E, Cecchin E, Del Bianco P, Menin C, Spolverato G, Giunco S, et al. Genetic variants of the TERT gene. telomere length, and circulating TERT as prognostic markers in rectal cancer patients. Cancers 2020; 12: 3115. doi: 10.3390/cancers12113115
  18. Yuan X, Dai M, Xu D. Telomere-related markers for cancer. Curr Top Med Chem 2020; 20: 410–32. doi: 10.2174/1568026620666200106145340
  19. Levstek T, Redenšek S, Trošt M, Dolžan V, Trebušak Podkrajšek K. Assessment of the telomere length and its effect on the symptomatology of parkinson’s disease. Antioxidants 2021; 10: 137. doi: 10.3390/antiox10010137
  20. Borges G, Criqui M, Harrington L. Tieing together loose ends: telomere instability in cancer and aging. Mol Oncol 2022; 16: 3380–96. doi: 10.3390/antiox10010137
  21. Cigan SS, Meredith JJ, Kelley AC, Yang T, Langer EK, Hooten AJ, et al. Predicted leukocyte telomere length and risk of germ cell tumours. Br J Cancer 2022; 127: 301–12. doi: 10.1038/s41416-022-01798-3
  22. Au AY, Hackl T, Yeager TR, Cohen SB, Pass HI, Harris CC, et al. Telomerase activity in pleural malignant mesotheliomas. Lung Cancer 2011; 73: 283–8. doi: 10.1016/j.lungcan.2010.12.023
  23. Aida S, Aida J, Naoi M, Kato M, Tsuura Y, Natsume I, et al. Measurement of telomere length in cells from pleural effusion: asbestos exposure causes telomere shortening in pleural mesothelial cells. Pathol Int 2018; 68: 503–8. doi: 10.1111/pin.12710
  24. Alfudhili KM, Lynch DA, Laurent F, Ferretti GR, Dunet V, Beigelman-Aubry C. et al. Focal pleural thickening mimicking pleural plaques on chest computed tomography: tips and tricks. Br J Radiol 2016; 89: 20150792. doi: 10.1259/bjr.20150792
  25. Kim Y, Myong JP, Lee JK, Kim JS, Kim YK, Jung SH, et al. CT characteristics of pleural plaques related to occupational or environmental asbestos exposure from South Korean asbestos mines. Korean J Radiol 2015; 16: 1142–52. doi: 10.3348/kjr.2015.16.5.1142
  26. Wolff H, Vehmas T, Oksa P, Rantanen J, Vainio H. Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. Scand J Work Environ Health 2015; 41: 5–15. doi: 10.5271/sjweh.3462
  27. Chapel DB, Schulte JJ, Husain AN, Krausz T. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res 2020; 9(Suppl 1): S3–27. doi: 10.21037/tlcr.2019.11.29
  28. Munkholm-Larsen S, Cao CQ, Yan TD. Malignant peritoneal mesothelioma. World J Gastrointest Surg 2009; 1: 38–48. doi: 10.4240/wjgs.v1.i1.38
  29. Berzenji L, Van Schil PE, Carp L. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res 2018; 7: 543–9. doi: 10.21037/tlcr.2018.07.05
  30. Franko A, Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V. NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases. J Med Biochem 2020; 39: 91–9. doi: 10.2478/jomb-2019-0025
  31. Klebe S, Leigh J, Henderson DW, Nurminen M. Asbestos. smoking and lung cancer: an update. Int J Environ Res Public Health 2019; 17: 258. doi: 10.3390/ijerph17010258
  32. Levstek T, Redenšek S, Trošt M, Dolžan V, Trebušak Podkrajšek K. Assessment of the telomere length and its effect on the symptomatology of Parkinson’s disease. Antioxidants 2021; 10: 137. doi: 10.3390/antiox10010137.
  33. Lulkiewicz M, Bajsert J, Kopczynski P, Barczak W, Rubis B. Telomere length: how the length makes a difference. Mol Biol Rep 2020; 47: 7181–8. doi: 10.1007/s11033-020-05551-y
  34. Havas A, Yin S, Adams PD. The role of aging in cancer. Mol Oncol 2022; 16: 3213–9. doi: 10.1002/1878-0261.13302
  35. Kusamura S, Baratti D, De Simone M, Pasqual EM, Ansaloni L, Marrelli D, et al. Diagnostic and therapeutic pathway in diffuse malignant peritoneal mesothelioma. Cancers 2023; 15: 662. doi: 10.3390/cancers15030662
  36. Zhou M, Jiang B, Xiong M, Zhu X. Association between TERT rs2736098 polymorphisms and cancer risk-a meta-analysis. Front Physiol 2018; 9: 377. doi: 10.3389/fphys.2018.00377
  37. Wang M, Sun Y. Telomerase reverse transcriptase rs2736098 polymorphism is associated with lung cancer: a meta-analysis. J Int Med Res 2020; 48: 300060520936173. doi: 10.1177/0300060520936173
  38. Holesova Z, Krasnicanova L, Saade R, Pös O, Budis J, Gazdarica J, et al. Telomere length changes in cancer: insights on carcinogenesis and potential for non-invasive diagnostic strategies. Genes 2023; 14: 715. doi: 10.3390/genes14030715
  39. Arimura-Omori M, Kiyohara C, Yanagihara T, Yamamoto Y, Ogata-Suetsugu S, Harada E, et al. Association between telomere-related polymorphisms and the risk of IPF and COPD as a precursor lesion of lung cancer: findings from the Fukuoka tobacco-related lung disease (FOLD) registry. Asian Pac J Cancer Prev 2020; 21: 667–73. doi: 10.31557/APJCP.2020.21.3.667
  40. Cornean CI, Catana A, Maniu AA, Do polymorphisms of the TERT, GSTM1, and GSTT1 genes increase laryngeal cancer susceptibility in smokers of Romanian descent? Medicina (Kaunas) 2022; 58: 1106. doi: 10.3390/medicina5808110
  41. He G, Song T, Zhang Y, Chen X, W, Chen H, et al. TERT rs10069690 polymorphism and cancers risk: a meta-analysis. Mol Genet Genomic Med 2019; 7: e00903. doi: 10.1002/mgg3.903
  42. Benitez-Buelga C, Sanchez-Barroso L, Gallardo M, Apellániz-Ruiz M, Inglada-Pérez L, Yanowski K, et al. Impact of chemotherapy on telomere length in sporadic and familial breast cancer patients. Breast Cancer Res Treat 2015; 149: 385–94. doi: 10.1007/s10549-014-3246-6
  43. Zins K, Peka E, Miedl H, Ecker S, Abraham D, Schreiber M. Association of the telomerase reverse transcriptase rs10069690 polymorphism with the risk, age at onset and prognosis of triple negative breast cancer. Int J Mol Sci 2023; 24: 1825. doi: 10.3390/ijms24031825
  44. Schneider CV, Schneider KM, Teumer A, Rudolph KL, Hartmann D, Rader DJ, et al. Association of telomere length with risk of disease and mortality. JAMA Intern Med 2022; 182: 291–300. doi: 10.1001/jamainternmed.2021.7804
  45. Hamada T, Yuan C, Bao Y, Mingfeng Zhang, Natalia Khalaf, Ana Babic, et al. Prediagnostic leukocyte telomere length and pancreatic cancer survival. Cancer Epidemiol Biomarkers Prev 2019; 28: 1868–75. doi: 10.1158/1055-9965.EPI-19-0577
  46. Ma R, Liu C, Lu M, Yuan X, Cheng G, Kong F, et al. The TERT locus genotypes of rs2736100-CC/CA and rs2736098-AA predict shorter survival in renal cell carcinoma. Urol Oncol 2019; 37: 301.e1–10. doi: 10.1016/j.urolonc.2019.01.014
  47. Pandith AA, Wani ZA, Qasim I, Afroze D, Manzoor U, Amin I, et al. Association of strong risk of hTERT gene polymorphic variants to malignant glioma and its prognostic implications with respect to different histological types and survival of glioma cases. J Gene Med 2020; 22: e3260. doi: 10.1002/jgm.3260
  48. Nie X, Shang J, Wang W. TERT genetic polymorphism rs2736100 is associated with an aggressive manifestation of papillary thyroid carcinoma. Front Surg 2022; 9: 1019180. doi: 10.3389/fsurg.2022.1019180
DOI: https://doi.org/10.2478/raon-2024-0009 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Page range: 87 - 98
Submitted on: Aug 25, 2023
|
Accepted on: Sep 13, 2023
|
Published on: Feb 21, 2024
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2024 Ana Mervic, Katja Goricar, Tanja Blagus, Alenka Franko, Katarina Trebusak-Podkrajsek, Metoda Dodic Fikfak, Vita Dolzan, Viljem Kovac, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.